


wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 750 and 15,000 and the molecular weight represented by the polyoxyethylene portion of the copolymer [constitutes between] is approximately 1% and] less than 50% of the copolymer.

5. (Amended) The composition of Claim 1 wherein the compound [capable of altering nucleic acid sequence function] for altering gene activity is selected from the group consisting of genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, and ribozymes.

6. (Amended) The composition of [Claim 7] Claim 1 further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of a low molecular weight alcohol.

8. (Amended) The composition of Claim 7 further comprising an expression vector, and wherein the compound [capable of altering nucleic acid sequence function] for altering gene activity is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.

9. (Amended) A method of delivering a compound [capable of altering nucleic acid sequence function] for altering gene activity to a human or animal comprising, the step of administering to a human or animal a composition comprising a compound [capable of altering nucleic acid sequence function] for altering gene activity admixed with a nonionic block copolymer, wherein the block copolymer has the following formula:



wherein the molecular weight represented by the polyoxypropylene portion of the copolymer is between approximately 750 and 15,000 and the molecular weight represented